SAMJIN PHARMACEUTICAL CO., LTD.;INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION;BAMICHEM CO., LTD.
发明人:
Eui Hwan CHO,Hee Jong SHIN,Min Hyo KI,Ho Seok KWON,Jae Woong LEE,Jeong Ho JOO,Keun Kuk LEE,Jong Min KIM,Yong Bin PARK,Sung Hyun KANG,Hyoung Min CHO,Hyun Tae KIM,Soon Kil AHN,Sung Pyo HONG,Sung Hye KIM
申请号：
US16074950
公开号：
US20190300531A1
申请日:
2017.01.11
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation.
